Company Update

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2020 Kewaunee Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-5286 38-0715562 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 2700 West Front Street Statesville, North Carolina 28677 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: 704-873-7202 N/A (Former name or former address, if changed since last report.) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $2.50 par value KEQU NASDAQ Global Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 8.01 Other Events On April 9, 2020, Kewaunee Scientific Corporation (“Kewaunee”) received approval from the Government of Karnataka, India to re-commence operations at its Bangalore, India manufacturing facility. The approval limits operations to 50% of staff capacity at the facility and is subject to several additional guidelines relating to employee health and safety. Kewaunee resumed operations at the facility in accordance with the approval on April 13, 2020. Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. (Registrant) Kewaunee Scientific Corporation Date: April 13, 2020 /s/ Donald T. Gardner III Donald T. Gardner III Vice President, Finance and Chief Financial Officer